Ensysce Biosciences (ENSC) Issues Mid-Year 2024 Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
Ensysce Biosciences Provides Mid-Year 2024 Update
July 23, 2024 10:32 AM EDT~ Ready to Commence PF614 Phase 3 Clinical Trial in 2024 ~
~ Continued Clinical Development of Overdose Protection Breakthrough Therapy ~
~ Identified Lead Clinical Candidate for Opioid Use Disorder Program ~
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ: ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today provides a Company review and update on a successful first half of 2024, including achievement of Breakthrough... More
